A hallmark event in neurodegenerative diseases (NDs) is the misfolding, aggregation, and
accumulation of proteins, leading to cellular dysfunction, loss of synaptic connections, and …

Biomarker discovery and development for clinical research, diagnostics and therapy
monitoring in clinical trials have advanced rapidly in key areas of medicine—most notably …

The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ 42), total
Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau 181) have proven diagnostic …

Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

Importance One characteristic histopathological event in Alzheimer disease (AD) is cerebral
amyloid aggregation, which can be detected by biomarkers in cerebrospinal fluid (CSF) and …

It is broadly acknowledged that the onset of dementia in Alzheimer's disease (AD) may be
modifiable by the management of risk factors. While several recent guidelines and …

Despite all scientific efforts and many protracted and expensive clinical trials, no new drug
has been approved by FDA for treatment of Alzheimer disease (AD) since 2003. Indeed …

Background A growing body of evidence suggests that the plasma concentration of the
neurofilament light chain (NfL) might be considered a plasma biomarker for the screening of …

Cells and their derived extracellular vesicles (EVs) or exosomes contain unique molecular
signatures that could be used as biomarkers for the detection of severe diseases such as …

Extracellular vesicles (EVs), including exosomes, microvesicles, and oncosomes, are nano-
sized particles enclosed by a lipid bilayer. EVs are released by virtually all eukaryotic cells …